SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for ...

SpringWorks Therapeutics is the perfect case study for rescuing a discontinued assets. It’s time to repeat the process for ...

The federal crackdown on DEI initiatives is unlikely to deter companies from designing more representative trials, as it’s ...

The Trump administration has started rehiring some of the FDA employees it fired last week, the latest chapter in a haphazard ...

Rise and shine! 🌅 Discover the top eight breathtaking spots across the U.S. where the sunrise is nothing short of magical.

DelveInsight's Advanced Therapy Medicinal Products Market Insights report provides the current and forecast market analysis, ...

US treasury yields are near their lowest levels of the year as traders bet on bigger interest rate cuts. Some bond traders ...

Ro Khanna (D-Calif.) posted a video on TikTok informing his 400,000 followers of “breaking news” that “the Trump ...

We maintain our fair value estimate of $187 per share. Xywav (for excessive daytime sleepiness), Epidiolex (for childhood epilepsy), and Rylaze (for leukemia) have continued to be Jazz’s primary ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Since, Viking's clinical data remain strong, and the company aims to launch a phase 3 trial for the injectable version of ...

BioSymetrics is a leading AI-powered drug discovery and data analytics company, focusing on phenotype-based insights to ...